A pledge to improve performance was made by Richard Brown, Pharmacia &Upjohn's chairman, when the company announced its financial results for the first three months of 1997. P&U had previously warned that the performance would not be good (Marketletter April 28).
Jan Ekberg, president and chief executive, said: "a number of actions have been implemented and others are now being launched" which will "significantly improve short- and long-term results of this company." Furthermore, the firm indicated that it has progressed in its search for a new chief executive, and expects to make an announcement in the near future.
Sales in the quarter were down 6.1% to $1.6 billion, net earnings declined 15.3% to $194 million before nonrecurring items, and earnings per share were down 15.9% to 37 cents. 5% of the sales decline was attributed to foreign exchange effects and trade inventory building.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze